IMMUNOTERAPIA NEL MIELOMA MULTIPLO E NEL LINFOMA DI HODGKIN: Ruolo nel paziente con MM ricaduto

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy

Patient Case and Question

Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida

Treatment strategies for relapsing and refractory myeloma

Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma

Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,

This talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse

This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is

Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014

Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,

Jefferies 2017 Healthcare Conference

Jefferies 2017 Healthcare Conference June 9, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The

Myeloma treatment algorithm 1999

Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

A Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma

A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut

Treatment strategies for relapsing and refractory myeloma

Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The

Myeloma 101 Updates and Pain Management Perspectives

Myeloma 101 Updates and Pain Management Perspectives Brian GM Durie, MD Thursday, November 19 th, 2015 Topics for Discussion 1. What to expect from ASH 2015 a preview Research Clinical pearls : New 101

Anticorpi monoclonali nel mieloma

Anticorpi monoclonali nel mieloma Elena Zamagni Seragnoli Institute of Hematology Bologna University Main Targets in Multiple Myeloma Plasma Cells and Drugs Tested Against Them Kinase inh Cell cycle inh

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.

Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

Daratumumab (Darzalex )

Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides

Treatment options in Myeloma. BritModis myeloma for the elderly care specialist

Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood

Clinical Advances in Immunotherapy in Myeloma. Webinar 1, June 14, 2017 Monoclonal Antibodies. Speakers

Clinical Advances in Immunotherapy in Myeloma Webinar 1, June 14, 2017 Monoclonal Antibodies Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut Faculty: Tom Martin,

Mieloma Múltiplo Tratamento do idoso

Mieloma Múltiplo Mieloma Múltiplo Tratamento do idoso Prof. Dra. Vania Tietsche de Moraes Hungria Professora Adjunta da Disciplina de Hematologia e Oncologia da Faculdade de Ciências Médicas da Santa Casa

TREATMENT OVERVIEW themmrf.org

MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti

GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma

GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking

Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future

Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff

Hematopoietic Stem Cell Transplant in Myeloma. Gary Simmons, DO

Hematopoietic Stem Cell Transplant in Myeloma Gary Simmons, DO Objectives What is the benefit of ASCT What is Upfront therapy and with novel agent era- does it include ASCT Is response before and after

Multiple myeloma Forecast DMKC Published on 07/04/2016

Multiple myeloma Forecast DMKC0157485 Published on 07/04/2016 Datamonitor Healthcare forecasts that the extended indications for these drugs will lead to considerable uptake across the treatment algorithm,

Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma

Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress

Managing Your Myeloma

Managing Your Myeloma Managing Your Myeloma Craig Emmitt Cole, MD Assistant Professor of Internal Medicine Multiple Myeloma and Plasma Cell Dyscrasia Program Division of Hematology/Oncology University

Novel Targets in Multiple Myeloma

Novel Targets in Multiple Myeloma Ajai Chari, MD Abstract Despite the availability of 5 classes of drugs for the treatment of multiple myeloma (MM), the disease remains incurable in most cases, with patients

Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders

Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders Proceedings from a Clinical Investigator Roundtable Discussion FACULTY Rafael

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

Integration of Novel Agents into the Care of Patients with Multiple Myeloma Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center Sagar Lonial, Emory University Journal Title: Clinical

Management of Multiple Myeloma: The Changing Paradigm. Clinical Trials

Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available

Novel Targets in Multiple Myeloma

MULTIPLE MYELOMA Novel Targets in Multiple Myeloma Douglas Tremblay, MD, and Ajai Chari, MD Abstract Despite the availability of 6 classes of drugs for the treatment of multiple myeloma (MM), the disease

Clinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

To learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation

ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Craig Emmitt Cole, MD University of Michigan Comprehensive Cancer Center What are Blood Cancers, What IS Multiple Myeloma?

TRANSCRIPT Multiple Myeloma Updates From the 2015 ASCO Annual Meeting and 20 th Congress of EHA

Welcome and Introduction Joan Levy, PhD [Slide 1] Hello everyone! [Slide 2] My name is Joan Levy, and I am Vice President of Research at the Multiple Myeloma Research Foundation (MMRF). I d like to welcome

Multiple Myeloma (MM): Diagnosis, Treatment and Side Effects Management. Transcript. Slide Name & Number

Question 1) Multiple myeloma is a disease of: a) Hematopoietic stem cells b) Reticulocytes c) Plasma cells d) Mature lymphocytes 2) What is the acronym for the criteria used to guide therapy initiation

Operator Greetings, and welcome to the Living With Myeloma: Managing Side Effects and Quality of Life telephone and Web education program.

WELCOME AND INTRODUCTION Operator Greetings, and welcome to the Living With Myeloma: telephone and Web education program. It is now my pleasure to introduce your moderator,. Thank you, Ms. Figueroa-Rivera.

Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know

Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended

Living With Myeloma Treatment and Side Effects Management

Slide 1: Welcome & Introductions OPERATOR: Hello, everyone, and welcome to Living With Myeloma Treatment and Side Effects Management, a free telephone/web education program. It is my pleasure to introduce

Immunotherapy in myeloma

Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to

GBI Research Report Guidance

THERAPY ANALYSIS Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments Published: July

RE: Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness and Value Draft Report dated April 7, 2016

Institute for Clinical and Economic Review Two Liberty Square, Ninth Floor Boston, Massachusetts 02109 publiccomments@icer-review.org RE: Treatment Options for Relapsed or Refractory Multiple Myeloma:

Tumor Board: Challenging Cases in Multiple Myeloma Patient Care

Tumor Board: Challenging Cases in Multiple Myeloma Patient Care The activity is provided by This activity is supported by educational funding provided by Amgen. Activity Information Release date: May 13,

pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016

pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

1 Introduction. Pamela L. Clemens 1 Xiaoyu Yan. Nedjad Losic 5 Imran Khan. Kristen Lantz 1 Honghui Zhou

Clin Pharmacokinet (2017) 56:915 924 DOI 10.1007/s40262-016-0477-1 ORIGINAL RESEARCH ARTICLE Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After

MULTIPLE MYELOMA. on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple

MULTIPLE MYELOMA SANDRA E. KURTIN, RN, MS AOCN, ANP-C Our next session is on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma. Pleased to have here with us today, Ms.

The MMRF CoMMpass Study SM in Context

The MMRF CoMMpass Study SM in Context A Look at the Past, Present, and Future of Multiple Myeloma Research themmrf.org Table of Contents General Overview... 3 Multiple Myeloma Research Foundation: Who

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures

Additionally, given the prevalence of patients with multiple myeloma who are double refractory to a PI and an IMiD, perc felt that a phase 3 randomized trial could have been conducted in this population

Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing

Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil

Immunotherapy in Hemato-Oncology

ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter

Thalidomide Therapy. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Multiple Myeloma Cancer of the Bone Marrow Understanding Thalidomide Therapy u-thal_en_2017_e1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)

Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions

Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &

pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation

pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation Ixazomib (Ninlaro) for Multiple Myeloma Myeloma Canada June 29, 2017 1. Feedback

bb2121 for relapsed and refractory multiple myeloma

NIHR Innovation Observatory Evidence Briefing: February 2018 bb2121 for relapsed and refractory multiple myeloma NIHRIO (HSRIC) ID: 19353 NICE ID: 9787 LAY SUMMARY Multiple myeloma (MM) is a rare, incurable

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique

Clinical Roundtable Monograph

Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y A p r i l 2 0 1 2 Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma: A Post-ASH

Leading Voices. Jonathan Montgomery, Chair of the Health Research Authority (HRA) Patient Experience David Corrin My Myeloma Story

Summer 2016 www.myeloma.org.uk Leading Voices Jonathan Montgomery, Chair of the Health Research Authority (HRA) Patient Experience David Corrin My Myeloma Story Medical MattersMyelo Myeloma NICE guidelines

Pharmaceutical Approvals Monthly

Pharmaceutical Approvals Monthly January 2011 Volume 16 Number 1 Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials Bolstered by a huge patient database, the Multiple Myeloma Research

Final published version:

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group

Vision Statement for Multiple Myeloma: Future Directions

Vision Statement for Multiple Myeloma: Future Directions Kenneth C. Anderson Abstract There has been great progress in the management and patient outcome in multiple myeloma due to the use of novel agents

Supplementary Appendix

Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus

NINLARO. Understanding. (ixazomib) capsules. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation

Multiple Myeloma Cancer of the Bone Marrow Understanding NINLARO (ixazomib) capsules u-nin_en_2018_f4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada)

CAREGIVER GUIDE themmrf.org

MULTIPLE MYELOMA CAREGIVER GUIDE themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Sagar Lonial, Emory University B Durie, Cedars-Sinai Outpatient Cancer Center A Palumbo, University of

Syddansk Universitet. DOI: /cclm Publication date: Document version Publisher's PDF, also known as Version of record

Syddansk Universitet Monitoring multiple myeloma patients treated with daratumumab teasing out monoclonal antibody interference McCudden, Christopher; Axel, Amy E; Slaets, Dominique; Dejoie, Thomas; Clemens,

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT)

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA

Appendix A WinBUGS code

A systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma van Beurden-Tan, et al Appendix A WinBUGS code Model code: model{ for(i in

Addressing THE. Introduction

Addressing THE CURRENT CHALLENGES OF multiple myeloma TREATMENT This CME-certified activity is based on information presented at a satellite symposium held on December 7, 2012, in Atlanta, Georgia. Faculty

Myeloma. Anne Grace, myeloma survivor. Support for this publication provided by

Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2017 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant

AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA

January 29, 2015 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS Amgen (NASDAQ:AMGN) and its subsidiary Onyx

Introduction POSITION PAPER

POSITION PAPER doi:10.1111/imj.13707 Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-cd38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Original Article Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma H.M. Lokhorst, T. Plesner, J.P. Laubach, H. Nahi, P. Gimsing, M. Hansson, M.C. Minnema, U. Lassen, J. Krejcik, A. Palumbo,

Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies

Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies John R. Mills 1 * and David L. Murray 1 Background: Since the first monoclonal

POST-ASH Issue 2, Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL

POST-ASH Issue 2, 2013 Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL For more visit ResearchToPractice.com/5MJCASH2013 CME Information OVERVIEW OF ACTIVITY The

XII Encuentro de Cooperación Farma-Biotech

XII Encuentro de Cooperación Farma-Biotech Santiago de Compostela, 26 de septiembre de 2014 Cannabinoid agents for the treatment of multiple myeloma and related conditions XII Encuentro de Cooperación

RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY)

RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY) Larry D. Anderson, Jr, MD, PhD Internal Medicine Grand Rounds University of Texas Southwestern Medical Center March 9, 2018 This

Myeloma Treatment and Side Effects Management Update

1 Slide 1: Myeloma Treatment and Side Effects Management OPERATOR: Hello, everyone, and welcome to Myeloma Treatment and Side Effects Management Update, a free telephone/web education program. It is my

Immunotherapy for Myeloma: with highlights from ASH 2015

Immunotherapy for Myeloma: with highlights from ASH 2015 Adam D. Cohen, MD Assistant Professor Division of Hematology/Oncology Abramson Cancer Center University of Pennsylvania January 22, 2016 Outline

Myeloma Update on Treatment and Side Effects Management November 7, 2013 Speaker: Asher A. Chanan-Khan, MD

Slide 1 Welcome & Introductions OPERATOR: Hello, everyone, welcome to Myeloma Update on Treatment and, a free telephone-web education program. It is my pleasure to introduce your moderator, Lauren Berger,

1 st European Myeloma Network Meeting

PRELIMINARY PROGRAM 1 st European www.emn2018.com UNDER THE AUSPICES OF: CITTÀ DI TORINO REGIONE PIEMONTE UNIVERSITÀ DI TORINO AZIENDA OSPEDALIERO-UNIVERSITARIA Città della Salute e della Scienza di Torino

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Biology of Human Tumors Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution Min Tang 1,2, Rui Zhao 1,2, Helgi van de Velde 3, Jennifer G.

DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS

DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com

Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison

Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested

DARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING. Dr. Jennifer Duncan Hematopathology Resident March 18, 2017

DARATUMUMAB HARD TO PRONOUNCE - EVEN HARDER ON BLOOD BANK TESTING Dr. Jennifer Duncan Hematopathology Resident March 18, 2017 Goals and Objectives: Briefly describe the use of dara in the treatment of

Clinical Advances in Immunotherapy in Myeloma. Webinar 2, July 26, 2017 Vaccines for Myeloma (and Other Advances in Immunotherapy) Tech Support

Clinical Advances in Immunotherapy in Myeloma Webinar 2, July 26, 2017 Vaccines for Myeloma (and Other Advances in Immunotherapy) Tech Support Unable to hear the presentation? Refresh your browser by tapping

Understanding. (pomalidomide) capsules. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Multiple Myeloma Cancer of the Bone Marrow Understanding POMALYST (pomalidomide) capsules u-pom_en_2017_m3 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873)

Myeloma Today. Special Events

Myeloma Today WINTER 2013/2014 Volume 9 Number 9 A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and

Selinexor Mechanism of Action

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone (SPd) in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure Christine

GSK 916: anti-bcma ADC Investor Call. Tuesday, 12 December 2017

GSK 916: anti-bcma ADC Investor Call Tuesday, 12 December 2017 Luke Miels: Thanks Alisa, and good afternoon and thanks for joining this GSK investor and analyst conference call to discuss the data that

Multiple Myeloma Patient Handbook

Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:

My life with myeloma. Ed Jones Patient experience. Myeloma research Taking a drug from the laboratory into early phase clinical trials

WINTER 2016 www.myeloma.org.uk My life with myeloma Ed Jones Patient experience Myeloma research Taking a drug from the laboratory into early phase clinical trials Medical mattersmyelo Immunotherapy: Focus

Concise Review. of the Disease and Treatment Options. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Multiple Myeloma Cancer of the Bone Marrow Concise Review of the Disease and Treatment Options 2017 Edition Prepared by Brian G.M. Durie, MD A publication of the International Myeloma Foundation Improving

What do you do, with an M protein?

What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily

7/6/2017. Learning Objectives

Learning Objectives Monoclonal Antibody Therapeutics Potential Interferents on Protein Electrophoresis and Related Tests Maria Alice V. Willrich, Ph.D., DABCC At the end of the presentation, participants

Selinexor Mechanism of Action

Selinexor in Combination with Weekly Low-Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with ractory Multiple Myeloma Nizar J. Bahlis 1, Heather

Myeloma Today. Supportive Care. This issue of Myeloma Today is supported by Binding Site, Celgene Corporation,

Myeloma Today Winter 2012/2013 Volume 9 Number 4 A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and

Do you think you'd be here today if you had not gone to M. D. Anderson?

Advances in Treatment of Multiple Myeloma Webcast November 13, 2007 Michael Wang, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,

COMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA

Blood First Edition Paper, prepublished online August 23, 2005; DOI 10.1182/blood-2005-07-2817 COMBINATION THERAPY WITH LENALIDOMIDE PLUS DEXAMETHASONE (REV/DEX) FOR NEWLY DIAGNOSED MYELOMA S. Vincent

Infopack for relapsed and/or refractory myeloma patients. Infoline:

Infopack for relapsed and/or refractory myeloma patients. 1 1 What is relapsed myeloma? 2 How will I know if I am relapsing? 3 Can the timing of relapse be predicted? 4 Treatment at relapse 5 Refractory